No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma

Endocrine Journal

Volumn 53, Issue 5, 2006, Pages 615-620

  Kumagai, Atsushi ^a,b   Namba, Hiroyuki ^a,b   Shu, Takakura ^a   Inamasu, Eiko ^a   Saenko, Vladimir A ^a   Ohtsuru, Akira ^a,b   Yamashita, Shunichi ^a,b  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

ARAF; BRAF; CRAF; MET; Papillary thyroid carcinoma

Indexed keywords

A RAF KINASE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE RAS; PAPILLARY CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA; THYROID CELL;

CARCINOMA, PAPILLARY; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS A-RAF; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTORS, GROWTH FACTOR; THYROID GLAND; THYROID NEOPLASMS;

EID: 33750627809     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-058     Document Type: Article

References (41)

1. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457.
2. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397.
3. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M (2003) BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22: 4578-4580.
4. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627.
5. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA (2003) High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63: 4561-4567.
6. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED, Wynford-Thomas D (1988) Activated ras oncogenes in human thyroid cancers. Cancer Res 48: 4459-4463.
7. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA (1990) H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 71: 223-229.
8. Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13: 3-16.
9. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30: 216-222.
10. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S, Thomas GA, Bogdanova TI, Tronko MD, Nagayasu T, Shibata Y, Yamashita S (2004) Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4280-4284.
11. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simoes M (2004) BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4267-4271.
12. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE (2004) Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209: 1-6.
13. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646-6656.
14. Di Renzo MF, Olivero M, Ferro S, Prat M, Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R, Pierotti MA, et al. (1992) Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7: 2549-2553.
15. Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, Hayashi T, Maeda S, Ichinose M, Kanematsu T, Yamashita S (2002) Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 87: 3433-3440.
16. Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST (2002) Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 62: 5126-5128.
17. Nakashima M, Meirmanov S, Naruke Y, Kondo H, Saenko V, Rogounovitch T, Shimizu-Yoshida Y, Takamura N, Namba H, Ito M, Abrosimov A, Lushnikov E, Roumiantsev P, Tsyb A, Yamashita S, Sekine I (2004) Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. J Pathol 202: 446-455.
18. Hedinger C, Williams ED, Sobin LH (1989) The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63: 908-911.
19. Hayashida N, Namba H, Kumagai A, Hayashi T, Ohtsuru A, Ito M, Saenko VA, Maeda S, Kanematsu T, Yamashita S (2004) A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 14: 910-915.
20. Kawabe Y, Eguchi K, Shimomura C, Mine M, Otsubo T, Ueki Y, Tezuka H, Nakao H, Kawakami A, Migita K, Yamashita S, Matsunaga M, Ishikawa N, Ito K, Nagataki S (1989) Interleukin-1 production and action in thyroid tissue. J Clin Endocrinol Metab 68: 1174-1183.
21. Huleihel M, Goldsborough M, Cleveland J, Gunnell M, Bonner T, Rapp UR (1986) Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol Cell Biol 6: 2655-2662.
22. McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E, McMahon M (1998) Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 12: 1903-1929.
23. Hagemann C, Rapp UR (1999) Isotype-specific functions of Raf kinases. Exp Cell Res 253: 34-46.
24. Storm SM, Cleveland JL, Rapp UR (1990) Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 5: 345-351.
25. Winer MA, Wadewitz AG, Wolgemuth DJ (1993) Members of the raf gene family exhibit segment-specific patterns of expression in mouse epididymis. Mol Reprod Dev 35: 16-23.
26. Luckett JC, Huser MB, Giagtzoglou N, Brown JE, Pritchard CA (2000) Expression of the A-raf protooncogene in the normal adult and embryonic mouse. Cell Growth Differ 11: 163-171.
27. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR (1994) The ins and outs of Raf kinases. Trends Biochem Sci 19: 474-480.
28. Chong H, Vikis HG, Guan KL (2003) Mechanisms of regulating the Raf kinase family. Cell Signal 15: 463-469.
29. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ (1997) Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272: 4378-4383.
30. Papin C, Denouel A, Calothy G, Eychene A (1996) Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system. Oncogene 12: 2213-2221.
31. Papin C, Denouel-Galy A, Laugier D, Calothy G, Eychene A (1998) Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. J Biol Chem 273: 24939-24947.
32. Catling AD, Reuter CW, Cox ME, Parsons SJ, Weber MJ (1994) Partial purification of a mitogen-activated protein kinase kinase activator from bovine brain. Identification as B-Raf or a B-Raf-associated activity. J Biol Chem 269: 30014-30021.
33. Pritchard CA, Samuels ML, Bosch E, McMahon M (1995) Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 15: 6430-6442.
34. Jaiswal RK, Moodie SA, Wolfman A, Landreth GE (1994) The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras. Mol Cell Biol 14: 6944-6953.
35. Reuter CW, Catling AD, Jelinek T, Weber MJ (1995) Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators. J Biol Chem 270: 7644-7655.
36. Huser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, Giblett S, Sun XM, Brown J, Marais R, Pritchard C (2001) MEK kinase activity is not necessary for Raf-1 function. Embo J 20: 1940-1951.
37. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa Jr C, Knauf JA, Zhang L, Taira K, Fagin JA (2006) BRAF mediates RET/PTC-induced MAPK activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147: 1014-1019.
38. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25: 527-533.
39. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Min WS, Kim SH, Lee JY, Yoo NJ, Lee SH (2005) Mutational analysis of the ARAF gene in human cancers. Apmis 113: 54-57.
40. Ruco LP, Stoppacciaro A, Ballarini F, Prat M, Scarpino S (2001) Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. J Pathol 194: 4-8.
41. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68-73.